US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Evofem Biosciences, Inc.

0.0093

+0.00033.33%

Volume:166.17K

Turnover:1.54K

Market Cap:1.18M

PE:-0.19

High:0.0094

Open:0.0091

Low:0.0090

Close:0.0090

52wk High:0.0200

52wk Low:0.0061

Shares:126.69M

Float Shares:113.35M

Volume Ratio:1.31

T/O Rate:0.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0489

EPS(LYR):-0.1200

ROE:-387.27%

ROA:-9.63%

PB:-0.02

PE(LYR):-0.08

Loading ...

Overview Company News Filings

Evofem CEO Demands Overhaul of Women’s Health at Fierce JPM Week 2026

Evofem Biosciences Inc. held annual shareholder meeting

Evofem Biosciences Q3 net sales rise

Evofem Biosciences Q3 Pretax Profit USD -1.573 Million

THOMSON REUTERS

Evofem Biosciences Inc. Announces Date for Upcoming Annual Meeting of Stockholders

Evofem Biosciences Inc: Delivered Notice of Termination to Aditxt Notifying That Co Was Exercising Its Right to Terminate Merger Agreement

THOMSON REUTERS

Press Release: Evofem Announces Voting Results from Special Meeting of Stockholders

Evofem Biosciences Amends Debt Terms with Adjuvant Funds

Evofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis

BRIEF-Evofem Anticipates Approval Of Merger With Aditxt At Upcoming Stockholder Meeting

Evofem Anticipates Approval of Merger With Aditxt at Upcoming Stockholder Meeting

THOMSON REUTERS

ADiTx Inc. Updates Merger Agreement with Evofem, Adjusts Equity Investment Dates and Amounts

Evofem Biosciences Secures New Patent for SOLOSEC, Extending Market Exclusivity into 2041

Evofem Biosciences Inc. Reports 16% Increase in Q2 2025 Net Sales; Net Loss of $1.8M and EPS of $(0.02)

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

THOMSON REUTERS

Evofem Biosciences Q2 Pretax Profit USD -1.777 Million

THOMSON REUTERS

ADiTx Inc. Announces Board Changes: Jeffrey Runge and Saundra Pelletier to Step Down, Pelletier to Join Adifem Post-Merger

Evofem Biosciences Inc. Increases Authorized Shares to 10,000 for Preferred Stock Dividends

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EVFM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EVFM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVFM\",,,,,undefined,":{"symbol":"EVFM","market":"US","secType":"STK","nameCN":"Evofem Biosciences, Inc.","latestPrice":0.0093,"timestamp":1770411600000,"preClose":0.009,"halted":0,"volume":166173,"delay":15,"changeRate":0.033333333333333326,"floatShares":113354642,"shares":126685925,"eps":-0.048867,"marketStatus":"Market Closed","change":0.0003,"latestTime":"02-06 16:00:00 EST Delay","open":0.0091,"high":0.0094,"low":0.009,"amount":1541.6225999999997,"amplitude":0.044444,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.048867,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"exchange":"PINK","adjPreClose":0.009,"volumeRatio":1.3105374245581867},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVFM\",,,,,undefined,":{"symbol":"EVFM","floatShares":113354642,"roa":"-9.63%","roe":"-387.27%","lyrEps":-0.12,"volumeRatio":1.3105374245581867,"shares":126685925,"dividePrice":0,"high":0.0094,"amplitude":0.044444,"preClose":0.009,"low":0.009,"week52Low":0.00605,"pbRate":"-0.02","psRate":"0.07","week52High":0.02,"institutionHeld":0,"latestPrice":0.0093,"eps":-0.048867,"divideRate":0,"volume":166173,"delay":15,"ttmEps":-0.048867,"open":0.0091,"prevYearClose":0.0095,"prevWeekClose":0.0088,"prevMonthClose":0.0088,"prevQuarterClose":0.0095,"fiveDayClose":0.0088,"twentyDayClose":0.0092,"sixtyDayClose":0.0089},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVFM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-11-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-08-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1691985600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVFM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVFM\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVFM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVFM","date":"2022-08-05","current":-0.166395,"percent":0.950893,"low":-6.597859,"twenty":-2.250243,"median":-1.289012,"eighty":-0.728459,"high":-0.031142,"avg":-1.49806,"sd":1.032744,"marketCap":31769672},"quantilePoints":[{"date":"2021-02-11","current":-2.507423,"twenty":-2.672813,"median":-1.632445,"eighty":-1.021168,"marketCap":286919409},{"date":"2021-02-19","current":-3.366908,"twenty":-2.71669,"median":-1.651829,"eighty":-1.024811,"marketCap":385268555},{"date":"2021-02-26","current":-2.848376,"twenty":-2.745246,"median":-1.655041,"eighty":-1.029338,"marketCap":325933946},{"date":"2021-03-05","current":-1.867672,"twenty":-2.747677,"median":-1.663725,"eighty":-1.032121,"marketCap":265786535},{"date":"2021-03-12","current":-1.676293,"twenty":-2.745246,"median":-1.660162,"eighty":-1.035221,"marketCap":238551624},{"date":"2021-03-19","current":-1.588682,"twenty":-2.743329,"median":-1.655041,"eighty":-1.038349,"marketCap":226083769},{"date":"2021-03-26","current":-1.204757,"twenty":-2.736696,"median":-1.653841,"eighty":-1.038718,"marketCap":171447831},{"date":"2021-04-01","current":-1.233,"twenty":-2.727622,"median":-1.645078,"eighty":-1.04011,"marketCap":175467057},{"date":"2021-04-09","current":-1.240046,"twenty":-2.726572,"median":-1.626629,"eighty":-1.040946,"marketCap":176469726},{"date":"2021-04-16","current":-1.099132,"twenty":-2.71669,"median":-1.619767,"eighty":-1.04998,"marketCap":156416348},{"date":"2021-04-23","current":-1.070949,"twenty":-2.71669,"median":-1.605319,"eighty":-1.04998,"marketCap":152405672},{"date":"2021-04-30","current":-1.055056,"twenty":-2.697285,"median":-1.589897,"eighty":-1.040946,"marketCap":150143944},{"date":"2021-05-07","current":-0.881622,"twenty":-2.676997,"median":-1.577001,"eighty":-1.04011,"marketCap":125462747},{"date":"2021-05-14","current":-0.740987,"twenty":-2.670023,"median":-1.573429,"eighty":-1.033139,"marketCap":125459522},{"date":"2021-05-21","current":-0.773593,"twenty":-2.664959,"median":-1.570648,"eighty":-1.021948,"marketCap":130980172},{"date":"2021-05-28","current":-0.728459,"twenty":-2.655531,"median":-1.567623,"eighty":-1.014684,"marketCap":123338388},{"date":"2021-06-04","current":-0.795167,"twenty":-2.64853,"median":-1.5627,"eighty":-1.010667,"marketCap":134632945},{"date":"2021-06-11","current":-0.94781,"twenty":-2.640264,"median":-1.559356,"eighty":-1.003779,"marketCap":160477457},{"date":"2021-06-18","current":-1.047104,"twenty":-2.607198,"median":-1.555597,"eighty":-1.003779,"marketCap":177289381},{"date":"2021-06-25","current":-1.083211,"twenty":-2.587359,"median":-1.554323,"eighty":-1.003779,"marketCap":183402808},{"date":"2021-07-02","current":-0.992944,"twenty":-2.577755,"median":-1.54827,"eighty":-1.003779,"marketCap":168119241},{"date":"2021-07-08","current":-0.868645,"twenty":-2.571247,"median":-1.543397,"eighty":-1.001923,"marketCap":147073769},{"date":"2021-07-16","current":-0.830462,"twenty":-2.570827,"median":-1.534287,"eighty":-1.001911,"marketCap":140608820},{"date":"2021-07-23","current":-0.837683,"twenty":-2.569976,"median":-1.527184,"eighty":-0.997201,"marketCap":141831505},{"date":"2021-07-30","current":-0.79598,"twenty":-2.566348,"median":-1.527184,"eighty":-0.989357,"marketCap":134770497},{"date":"2021-08-05","current":-0.721238,"twenty":-2.565456,"median":-1.525046,"eighty":-0.985216,"marketCap":122115703},{"date":"2021-08-13","current":-0.777143,"twenty":-2.558807,"median":-1.510765,"eighty":-0.977482,"marketCap":116628902},{"date":"2021-08-20","current":-0.693957,"twenty":-2.535025,"median":-1.509563,"eighty":-0.970593,"marketCap":104144873},{"date":"2021-08-26","current":-0.857569,"twenty":-2.527842,"median":-1.509563,"eighty":-0.967886,"marketCap":128698851},{"date":"2021-09-03","current":-0.906177,"twenty":-2.522882,"median":-1.501822,"eighty":-0.966863,"marketCap":135993649},{"date":"2021-09-10","current":-0.876599,"twenty":-2.521229,"median":-1.500822,"eighty":-0.963107,"marketCap":131554687},{"date":"2021-09-17","current":-0.840815,"twenty":-2.51909,"median":-1.498725,"eighty":-0.951877,"marketCap":126184474},{"date":"2021-09-24","current":-0.807824,"twenty":-2.515298,"median":-1.49021,"eighty":-0.949203,"marketCap":121233324},{"date":"2021-10-01","current":-0.76387,"twenty":-2.512963,"median":-1.485821,"eighty":-0.94602,"marketCap":114636965},{"date":"2021-10-06","current":-0.761491,"twenty":-2.512963,"median":-1.483516,"eighty":-0.944019,"marketCap":114279986},{"date":"2021-10-15","current":-0.741324,"twenty":-2.509639,"median":-1.470856,"eighty":-0.935834,"marketCap":111253421},{"date":"2021-10-22","current":-0.733671,"twenty":-2.500827,"median":-1.466227,"eighty":-0.933578,"marketCap":110104878},{"date":"2021-10-29","current":-0.716089,"twenty":-2.49643,"median":-1.463115,"eighty":-0.930358,"marketCap":107466334},{"date":"2021-11-05","current":-0.739117,"twenty":-2.49147,"median":-1.455373,"eighty":-0.92436,"marketCap":110922261},{"date":"2021-11-12","current":-0.728355,"twenty":-2.482486,"median":-1.447004,"eighty":-0.920137,"marketCap":109307125},{"date":"2021-11-19","current":-0.386369,"twenty":-2.475346,"median":-1.419951,"eighty":-0.911743,"marketCap":75046683},{"date":"2021-11-26","current":-0.368646,"twenty":-2.470234,"median":-1.413372,"eighty":-0.910828,"marketCap":71604324},{"date":"2021-12-03","current":-0.345128,"twenty":-2.465921,"median":-1.409387,"eighty":-0.907248,"marketCap":67036265},{"date":"2021-12-10","current":-0.403167,"twenty":-2.463597,"median":-1.40309,"eighty":-0.905738,"marketCap":78309582},{"date":"2021-12-17","current":-0.313295,"twenty":-2.456306,"median":-1.389572,"eighty":-0.903748,"marketCap":60853071},{"date":"2021-12-23","current":-0.34748,"twenty":-2.450022,"median":-1.381831,"eighty":-0.902029,"marketCap":67493071},{"date":"2021-12-31","current":-0.319174,"twenty":-2.445888,"median":-1.378837,"eighty":-0.897011,"marketCap":61995086},{"date":"2022-01-07","current":-0.336561,"twenty":-2.438566,"median":-1.374379,"eighty":-0.890009,"marketCap":65372187},{"date":"2022-01-14","current":-0.330546,"twenty":-2.435259,"median":-1.374379,"eighty":-0.887406,"marketCap":64203917},{"date":"2022-01-21","current":-0.359744,"twenty":-2.422033,"median":-1.373004,"eighty":-0.88461,"marketCap":69875182},{"date":"2022-01-28","current":-0.344601,"twenty":-2.410537,"median":-1.364205,"eighty":-0.879684,"marketCap":66933925},{"date":"2022-02-04","current":-0.364261,"twenty":-2.408407,"median":-1.361316,"eighty":-0.876997,"marketCap":70752685},{"date":"2022-02-11","current":-0.35121,"twenty":-2.407979,"median":-1.360635,"eighty":-0.873952,"marketCap":68217678},{"date":"2022-02-18","current":-0.3999,"twenty":-2.4055,"median":-1.357152,"eighty":-0.868989,"marketCap":77675059},{"date":"2022-02-25","current":-0.401239,"twenty":-2.4055,"median":-1.354255,"eighty":-0.866236,"marketCap":77935059},{"date":"2022-03-04","current":-0.423267,"twenty":-2.4055,"median":-1.3492,"eighty":-0.857291,"marketCap":82213674},{"date":"2022-03-11","current":-0.320697,"twenty":-2.398887,"median":-1.346995,"eighty":-0.853506,"marketCap":65804496},{"date":"2022-03-18","current":-0.329119,"twenty":-2.397234,"median":-1.344895,"eighty":-0.847851,"marketCap":67532661},{"date":"2022-03-25","current":-0.325812,"twenty":-2.388918,"median":-1.342548,"eighty":-0.840765,"marketCap":66854009},{"date":"2022-04-01","current":-0.301935,"twenty":-2.383963,"median":-1.338645,"eighty":-0.83736,"marketCap":61954723},{"date":"2022-04-08","current":-0.227428,"twenty":-2.374597,"median":-1.333793,"eighty":-0.827311,"marketCap":46666484},{"date":"2022-04-14","current":-0.208602,"twenty":-2.367475,"median":-1.327882,"eighty":-0.818669,"marketCap":42803424},{"date":"2022-04-22","current":-0.177964,"twenty":-2.354249,"median":-1.324122,"eighty":-0.811433,"marketCap":36516842},{"date":"2022-04-29","current":-0.158072,"twenty":-2.337716,"median":-1.320898,"eighty":-0.80387,"marketCap":32435119},{"date":"2022-05-06","current":-0.09804,"twenty":-2.330036,"median":-1.319106,"eighty":-0.796197,"marketCap":20117060},{"date":"2022-05-13","current":-0.079302,"twenty":-2.325012,"median":-1.317041,"eighty":-0.793147,"marketCap":15141105},{"date":"2022-05-20","current":-0.073245,"twenty":-2.319979,"median":-1.316551,"eighty":-0.779563,"marketCap":13984579},{"date":"2022-05-27","current":-0.067867,"twenty":-2.309914,"median":-1.316029,"eighty":-0.776301,"marketCap":12957856},{"date":"2022-06-03","current":-0.067242,"twenty":-2.299849,"median":-1.310904,"eighty":-0.774424,"marketCap":12838360},{"date":"2022-06-10","current":-0.072366,"twenty":-2.291941,"median":-1.307915,"eighty":-0.769174,"marketCap":13816734},{"date":"2022-06-17","current":-0.056191,"twenty":-2.289784,"median":-1.302231,"eighty":-0.761429,"marketCap":10728507},{"date":"2022-06-24","current":-0.062195,"twenty":-2.288346,"median":-1.300568,"eighty":-0.758763,"marketCap":11874923},{"date":"2022-07-01","current":-0.221009,"twenty":-2.282377,"median":-1.299044,"eighty":-0.754436,"marketCap":42197054},{"date":"2022-07-08","current":-0.244479,"twenty":-2.281505,"median":-1.297414,"eighty":-0.747488,"marketCap":46678157},{"date":"2022-07-15","current":-0.209401,"twenty":-2.275405,"median":-1.296606,"eighty":-0.743702,"marketCap":39980638},{"date":"2022-07-22","current":-0.185295,"twenty":-2.264621,"median":-1.294665,"eighty":-0.739566,"marketCap":35378254},{"date":"2022-07-29","current":-0.137119,"twenty":-2.253837,"median":-1.292774,"eighty":-0.734705,"marketCap":26179907},{"date":"2022-08-05","current":-0.166395,"twenty":-2.250243,"median":-1.289012,"eighty":-0.728459,"marketCap":31769672}],"updateTime":1770518749010},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVFM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606729490","title":"Evofem CEO Demands Overhaul of Women’s Health at Fierce JPM Week 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606729490","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606729490?lang=en_us&edition=fundamental","pubTime":"2026-01-26 15:10","pubTimestamp":1769411431,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. CEO Saundra Pelletier delivered a powerful keynote address at Fierce JPM Week 2026, calling for a fundamental reset in women’s health. Pelletier highlighted the historical neglect of women’s health issues, stating, “If men suffered from endometriosis, it would be solved by now,” and criticized the exclusion of women from clinical trials due to perceptions about hormonal complexity. She emphasized Evofem’s commitment to prioritizing transparency, education, and respect in their approach to women’s health. The full keynote, titled “Rebuilding Women’s Health from the Ground Up,” is available for on-demand viewing via Fierce Pharma. Register for Fierce JPM Week 2026 and scroll to \"Friday, January 23\" to access the session.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL8zZFgY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AWHL","EVFM","BK4584","BK4007"],"gpt_icon":0},{"id":"2586423298","title":"Evofem Biosciences Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586423298","media":"Reuters","labels":["shareholding","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586423298?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:49","pubTimestamp":1764193776,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. held its Annual Meeting of Stockholders on November 26, 2025. Stockholders approved the election of Kim Kamdar, Ph.D., Colin Rutherford, Lisa Rarick, and Tony O'Brien as directors. Approval was also granted for an amendment to the Certificate of Incorporation to authorize a one-time reverse stock split of the company's common stock at a ratio between 1-for-500 and 1-for-1,500, to be implemented at any time before November 26, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDLppVzq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4584","BK4007"],"gpt_icon":0},{"id":"2583661512","title":"Evofem Biosciences Q3 net sales rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2583661512","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583661512?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:23","pubTimestamp":1763069024,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Q3 net sales riseOverviewEvofem Q3 net sales rise 10% yr/yr to $5.0 mlnCompany posts $1.0 mln operating income, reversing prior yr $2.4 mln lossOperating expenses fall 42% yr/yr, ai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP17R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4007","EVFM"],"gpt_icon":0},{"id":"2583511761","title":"Evofem Biosciences Q3 Pretax Profit USD -1.573 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583511761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583511761?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:05","pubTimestamp":1763067901,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLXE87230:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVFM","BK4007","BK4584"],"gpt_icon":0},{"id":"2577571894","title":"Evofem Biosciences Inc. Announces Date for Upcoming Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2577571894","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577571894?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:53","pubTimestamp":1761000822,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. will hold its 2025 Annual Meeting of Stockholders on [date]. At the meeting, shareholders will vote on several proposals, including the ratification of BPM LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, and a proposal to authorize the Board, at its discretion, to adjourn the Annual Meeting to another place, or to a later date or dates, if necessary or appropriate, to solicit additional proxies in favor of the listed proposals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL2pD03Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4007","BK4584"],"gpt_icon":0},{"id":"2577899181","title":"Evofem Biosciences Inc: Delivered Notice of Termination to Aditxt Notifying That Co Was Exercising Its Right to Terminate Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2577899181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577899181?lang=en_us&edition=fundamental","pubTime":"2025-10-21 05:59","pubTimestamp":1760997565,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nFWN3VZ02M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ADTX","EVFM","BK4584","BK4139"],"gpt_icon":0},{"id":"2577893924","title":"Press Release: Evofem Announces Voting Results from Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2577893924","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577893924?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:19","pubTimestamp":1760991540,"startTime":"0","endTime":"0","summary":"-- Evofem Shareholders Did Not Approve the Merger with Aditxt --. -- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales --. \"With the outcome of this meeting, we are pivoting to focus our efforts on regaining a national listing for Evofem's stock and securing capital to catalyze our growth trajectory and better position us to deliver sustainable positive EBITDA in 2027,\" said Saundra Pelletier, CEO of Evofem Biosciences. \"We are grateful to Aditxt for its support of Evofem and our mission through its meaningful investments, and we look forward to a fruitful  collaboration to commercialize the Mitomic diagnostic tests for women's health conditions , including endometriosis and ovarian cancer, under our September 2024 agreement.\". The Company commercializes two FDA-approved sexual health products: PHEXXI  vaginal gel for hormone-free, on-demand contraception, and SOLOSEC  2 g oral granules, a single dose oral 5-nitroimidazole drug indicated for the t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4099","BK4588","BK4604","R","BK4096","BK4139","BK4022","BK4232","BK4120","BK4585","BV","ADTX","TM","03160","BK4584","BK4007","EVFM"],"gpt_icon":1},{"id":"2576606069","title":"Evofem Biosciences Amends Debt Terms with Adjuvant Funds","url":"https://stock-news.laohu8.com/highlight/detail?id=2576606069","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576606069?lang=en_us&edition=fundamental","pubTime":"2025-10-18 04:06","pubTimestamp":1760731595,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. announced an amendment to its existing agreement with Adjuvant Global Health Technology Fund, adjusting the repayment timeline for certain convertible notes. The updated terms specify that the notes will be due either six months from the amendment date, upon a change of control, or in the event of acceleration. Prepayment is restricted for six months following the amendment unless Adjuvant approves otherwise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 17, 2025, and is solely respons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL4gp3pQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4007","BK4584"],"gpt_icon":0},{"id":"2572531937","title":"Evofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2572531937","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572531937?lang=en_us&edition=fundamental","pubTime":"2025-10-01 20:47","pubTimestamp":1759322849,"startTime":"0","endTime":"0","summary":"**Evofem Biosciences Inc. Announces Regulatory Filing for SOLOSEC in UAE** San Diego, Oct. 1, 2025 - Evofem Biosciences Inc. has announced that its licensee, Pharma 1, has submitted a regulatory application to the United Arab Emirates  Ministry of Health and Prevention for SOLOSEC  2g oral granules. This marks the first ex-U.S. regulatory filing for SOLOSEC, Evofem's FDA-approved single-dose oral treatment for bacterial vaginosis  and trichomoniasis. Pharma 1, which holds exclusive commercialization rights for SOLOSEC in the Middle East, aims to launch the product in the UAE in the first half of 2026, pending regulatory approval. No grant or funding was announced in connection with this regulatory review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL88mtnb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EVFM","BK4584"],"gpt_icon":0},{"id":"2566618628","title":"BRIEF-Evofem Anticipates Approval Of Merger With Aditxt At Upcoming Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2566618628","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566618628?lang=en_us&edition=fundamental","pubTime":"2025-09-09 21:29","pubTimestamp":1757424547,"startTime":"0","endTime":"0","summary":"BRIEF-Evofem Anticipates Approval Of Merger With Aditxt At Upcoming Stockholder MeetingSept 9 (Reuters) - Aditxt Inc ADTX.O:EVOFEM ANTICIPATES APPROVAL OF MERGER WITH ADITXT AT UPCOMING STOCKHOLDER ME","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nTUA48TCS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4139","BK4584","ADTX","BK4007"],"gpt_icon":0},{"id":"2566618507","title":"Evofem Anticipates Approval of Merger With Aditxt at Upcoming Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2566618507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566618507?lang=en_us&edition=fundamental","pubTime":"2025-09-09 21:28","pubTimestamp":1757424483,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nTUA48TCS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVFM","BK4139","BK4584","ADTX","BK4007"],"gpt_icon":0},{"id":"2562209347","title":"ADiTx Inc. Updates Merger Agreement with Evofem, Adjusts Equity Investment Dates and Amounts","url":"https://stock-news.laohu8.com/highlight/detail?id=2562209347","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562209347?lang=en_us&edition=fundamental","pubTime":"2025-08-28 04:31","pubTimestamp":1756326669,"startTime":"0","endTime":"0","summary":"Aditxt, Inc. has announced updates to its merger agreement with Evofem Biosciences, Inc. As per recent amendments, Aditxt will adjust the timing and amounts of its equity investments in Evofem. The Third Parent Equity Investment, originally set at $2 million by September 6, 2024, has been modified to $1.5 million with a new deadline of September 30, 2024. Additionally, the Fourth Parent Equity Investment, initially planned at $1 million by September 30, 2024, has been updated to $1.5 million with a deadline extension to October 31, 2024. These changes follow the merger agreement where Evofem will become a wholly owned subsidiary of Aditxt.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL3f4Ctp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4007","BK4139","ADTX","BK4584"],"gpt_icon":0},{"id":"2560192990","title":"Evofem Biosciences Secures New Patent for SOLOSEC, Extending Market Exclusivity into 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2560192990","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560192990?lang=en_us&edition=fundamental","pubTime":"2025-08-19 21:40","pubTimestamp":1755610824,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. announced the listing of a newly-issued U.S. Patent No. 12,280,037 in the FDA's Orange Book, covering its product SOLOSEC  2 g oral granules. This patent, which extends market exclusivity to December 2041, addresses the treatment of Trichomonas vaginalis infections with SOLOSEC. As the first and only single-dose oral treatment FDA-approved for both Bacterial Vaginosis and trichomoniasis, this development strengthens Evofem's patent portfolio and prolongs its market presence.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on August 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL4YlfVN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4007","BK4584"],"gpt_icon":0},{"id":"2559357957","title":"Evofem Biosciences Inc. Reports 16% Increase in Q2 2025 Net Sales; Net Loss of $1.8M and EPS of $(0.02)","url":"https://stock-news.laohu8.com/highlight/detail?id=2559357957","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559357957?lang=en_us&edition=fundamental","pubTime":"2025-08-14 20:46","pubTimestamp":1755175583,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. has reported its financial results for the second quarter of 2025, revealing an increase in net sales to $4.8 million, up from $4.2 million in the same period last year. The company also showed an improvement in its loss from operations, which decreased to $1.3 million from $1.4 million in the prior year quarter. However, the net loss attributable to common stockholders was $1.8 million, compared to a net income of $1.3 million in the second quarter of 2024. Evofem's CEO, Saundra Pelletier, expressed optimism about future sales, attributing anticipated growth to upcoming social media initiatives and positive press coverage for PHEXXI. The company continues to implement fiscal austerity measures but remains confident in its strategic direction. Total operating expenses for the quarter rose to $6.1 million from $5.5 million in the previous year, influenced by increased selling and marketing expenses, partially due to the Prescription Drug User Fee Act  fee for SOL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL2dvvYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM"],"gpt_icon":0},{"id":"2559957862","title":"Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2559957862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559957862?lang=en_us&edition=fundamental","pubTime":"2025-08-14 20:46","pubTimestamp":1755175563,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nTUA2LRVDQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4007","EVFM"],"gpt_icon":0},{"id":"2559865957","title":"Evofem Biosciences Q2 Pretax Profit USD -1.777 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2559865957","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559865957?lang=en_us&edition=fundamental","pubTime":"2025-08-14 20:46","pubTimestamp":1755175563,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nPLX6960C1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4584","EVFM"],"gpt_icon":0},{"id":"2558006574","title":"ADiTx Inc. Announces Board Changes: Jeffrey Runge and Saundra Pelletier to Step Down, Pelletier to Join Adifem Post-Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2558006574","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558006574?lang=en_us&edition=fundamental","pubTime":"2025-08-09 04:16","pubTimestamp":1754684210,"startTime":"0","endTime":"0","summary":"ADiTx Inc. announced that board members Jeffrey Runge and Saundra Pelletier will not stand for reelection at the 2025 Annual Meeting. Both will continue serving until their terms expire. Runge's departure is not due to any disagreement with the company. Pelletier, currently President and Executive Director of Evofem Biosciences, Inc., is expected to join the board and become President of Adifem after the merger between ADiTx and Evofem.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 08, 2025, and is solely responsible for t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nNDL114fmt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","ADTX","BK4139","EVFM","BK4007"],"gpt_icon":0},{"id":"2557584320","title":"Evofem Biosciences Inc. Increases Authorized Shares to 10,000 for Preferred Stock Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=2557584320","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557584320?lang=en_us&edition=fundamental","pubTime":"2025-08-06 18:03","pubTimestamp":1754474638,"startTime":"0","endTime":"0","summary":"Evofem Biosciences, Inc. has announced that its Board of Directors and the majority of holders of its Series E-1 Preferred Stock have approved an Amended and Restated Certificate of Designations. This decision will increase the total number of authorized shares from 2,300 to 10,000. The additional shares will be used for the payment of dividends \"in kind\" through the issuance of more Preferred Stock, and certain definitions within the company's governing documents have been updated.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Comm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDLb3jsnw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","EVFM","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}